{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:21:50Z","timestamp":1788466910407,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"DOI":"10.1007\/s11764-026-02116-z","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:06:01Z","timestamp":1788465961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors"],"prefix":"10.1007","author":[{"given":"Ada Z.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean C.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora B.","family":"Henrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Panattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Harkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salene M. W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"1","key":"2116_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1257\/jep.20231394","volume":"39","author":"P Herd","year":"2025","unstructured":"Herd P, Moynihan D. Administrative burdens in the social safety net. J Econ Perspect. 2025;39(1):129\u201350.","journal-title":"J Econ Perspect"},{"issue":"1","key":"2116_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101654","volume":"10","author":"J Gracie","year":"2025","unstructured":"Gracie J, Jimenez R, Winkfield KM. The burden of insurance prior authorization on cancer care: a review of evidence from radiation oncology. Adv Radiat Oncol. 2025;10(1):101654.","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"2116_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26339","volume":"64","author":"DS Dickens","year":"2017","unstructured":"Dickens DS, Pollock BH. Medication prior authorization in pediatric hematology and oncology. Pediatr Blood Cancer. 2017;64(6):e26339.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2116_CR4","doi-asserted-by":"publisher","first-page":"e2523807","DOI":"10.1001\/jamanetworkopen.2025.23807","volume":"8","author":"B Thom","year":"2025","unstructured":"Thom B, et al. Patient perspectives on prior authorization for cancer care. JAMA Netw Open. 2025;8(7):e2523807.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2116_CR5","doi-asserted-by":"publisher","first-page":"e2338182","DOI":"10.1001\/jamanetworkopen.2023.38182","volume":"6","author":"F Chino","year":"2023","unstructured":"Chino F, et al. The patient experience of prior authorization for cancer care. JAMA Netw Open. 2023;6(10):e2338182.","journal-title":"JAMA Netw Open"},{"key":"2116_CR6","unstructured":"Sausser L.\u00a0\u2018They won\u2019t help me\u2019: sickest patients face insurance denials despite policy fixes, in KFF Health News. 2025, KFF Health News."},{"key":"2116_CR7","unstructured":"Liss S and Sausser\u00a0L. The patient expected a free checkup. The Bill Was $1,430., in KFF Health News. 2025, Kaiser Family Foundation."},{"key":"2116_CR8","unstructured":"Appleby J.\u00a0He had short-term health insurance. His Colonoscopy Bill: $7,000., in KFF Health News. 2025, KFF Health News."},{"issue":"16","key":"2116_CR9","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.22.01799","volume":"41","author":"HM Khan","year":"2023","unstructured":"Khan HM, Ramsey S, Shankaran V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. J Clin Oncol. 2023;41(16):3051\u20138.","journal-title":"J Clin Oncol"},{"key":"2116_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205","author":"CK Altice","year":"2017","unstructured":"Altice CK, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djw205.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2116_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","volume":"10","author":"LG Gordon","year":"2017","unstructured":"Gordon LG, et al. A systematic review of financial toxicity among cancer survivors: we can\u2019t pay the co-pay. Patient. 2017;10(3):295\u2013309.","journal-title":"Patient"},{"issue":"2","key":"2116_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101469","volume":"36","author":"O Pail","year":"2023","unstructured":"Pail O, Knight TG. Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: a systematic review. Best Pract Res Clin Haematol. 2023;36(2):101469.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"2116_CR13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/cncr.33559","volume":"127","author":"JM Salsman","year":"2021","unstructured":"Salsman JM, et al. Systematic review of financial burden assessment in cancer: evaluation of measures and utility among adolescents and young adults and caregivers. Cancer. 2021;127(11):1739\u201348.","journal-title":"Cancer"},{"issue":"1","key":"2116_CR14","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2023-0229","volume":"10","author":"SM Jones","year":"2024","unstructured":"Jones SM, et al. Financial hardship after cancer: revision of a conceptual model and development of patient-reported outcome measures. Future Sci OA. 2024;10(1):FSO983.","journal-title":"Future Sci OA"},{"issue":"6","key":"2116_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s11764-022-01319-4","volume":"17","author":"SMW Jones","year":"2023","unstructured":"Jones SMW, et al. Association of financial worry with substance use, mental health, and quality of life in cancer patients. J Cancer Surviv. 2023;17(6):1824\u201333.","journal-title":"J Cancer Surviv"},{"issue":"1","key":"2116_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pon.5763","volume":"31","author":"C Benedict","year":"2022","unstructured":"Benedict C, et al. Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. Psychooncology. 2022;31(1):9\u201320.","journal-title":"Psychooncology"},{"issue":"7","key":"2116_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.clml.2021.02.001","volume":"21","author":"LA Evans","year":"2021","unstructured":"Evans LA, et al. The impact of socioeconomic risk factors on the survival outcomes of patients with newly diagnosed multiple myeloma: a cross-analysis of a population-based registry and a tertiary care center. Clin Lymphoma Myeloma Leuk. 2021;21(7):451-460 e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2116_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980\u20136.","journal-title":"J Clin Oncol"},{"key":"2116_CR19","doi-asserted-by":"crossref","unstructured":"Henrikson N, et al.\u00a0\u201cI felt super lucky:\u201d luck and administrative burden in addressing cancer-related financial hardship, in ASCO Quality Care Symposium. 2023: Boston, MA.","DOI":"10.1200\/OP.2023.19.11_suppl.198"},{"key":"2116_CR20","unstructured":"Jones SMW, et al.\u00a0Association of insurance and employment administrative burdens with financial hardship in cancer survivors, in Annual Meeting of the Multinational Association of Supportive Care in Cancer. 2025: Seattle, WA."},{"key":"2116_CR21","unstructured":"Henrikson NB, et al. Administrative burden associated with seeking financial assistance during cancer treatment: secondary qualitative analysis, in Annual Meeting of the Multinational Association of Supportive Care in Cancer. 2025: Seattle, WA."},{"key":"2116_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00954","author":"SMW Jones","year":"2026","unstructured":"Jones SMW, et al. Administrative burden as a potential cause of financial hardship and poor mental health in cancer: a mixed methods study. JCO Oncol Pract. 2026. https:\/\/doi.org\/10.1200\/OP-25-00954.","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"2116_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s11606-019-05002-w","volume":"34","author":"KR Yabroff","year":"2019","unstructured":"Yabroff KR, et al. Prevalence and correlates of medical financial hardship in the USA. J Gen Intern Med. 2019;34(8):1494\u2013502.","journal-title":"J Gen Intern Med"},{"key":"2116_CR24","unstructured":"Bichell RE. Workers' wages siphoned to pay medical bills, despite consumer protections, in KFF Health News. 2025, KFF Health News."},{"issue":"5","key":"2116_CR25","doi-asserted-by":"publisher","first-page":"e210859","DOI":"10.1001\/jamahealthforum.2021.0859","volume":"2","author":"AL Schwartz","year":"2021","unstructured":"Schwartz AL, et al. Measuring the scope of prior authorization policies: applying private insurer rules to Medicare part B. JAMA Health Forum. 2021;2(5):e210859.","journal-title":"JAMA Health Forum"},{"key":"2116_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcacs.2025.1452970","volume":"3","author":"SM Jones","year":"2025","unstructured":"Jones SM, et al. Development of item banks to assess financial hardship in cancer survivors using item response theory. Frontiers in Cancer Control and Society. 2025;3:1452970.","journal-title":"Frontiers in Cancer Control and Society"},{"key":"2116_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv410","author":"RD Tucker-Seeley","year":"2016","unstructured":"Tucker-Seeley RD, Yabroff KR. Minimizing the \u201cfinancial toxicity\u201d associated with cancer care: advancing the research agenda. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv410.","journal-title":"J Natl Cancer Inst"},{"key":"2116_CR28","unstructured":"2024 Prior Authorization State Law Chart. 2024, American Medical Association."},{"key":"2116_CR29","unstructured":"FDA Approves YERVOY\u2122 (ipilimumab) for the treatment of patients with newly diagnosed or previously-treated unresectable or metastatic melanoma, the deadliest form of skin cancer. 2011 6\/30\/26]; Available from: https:\/\/news.bms.com\/news\/details\/2011\/FDA-Approves-YERVOY-ipilimumab-for-the-Treatment-of-Patients-with-Newly-Diagnosed-or-Previously-Treated-Unresectable-or-Metastatic-Melanoma-the-Deadliest-Form-of-Skin-Cancer\/default.aspx."},{"key":"2116_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.2124","author":"N Gordon","year":"2017","unstructured":"Gordon N, et al. Trajectories of injectable cancer drug costs after launch in the United States. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/JCO.2016.72.2124.","journal-title":"J Clin Oncol"},{"key":"2116_CR31","unstructured":"Galewitz P, and Liss S.\u00a0Indiana takes on powerful hospitals by capping prices they charge employers, in KFF Health News. 2026, KFF Health News. Medicaid. 2026 6\/30\/26]; Available from:\u00a0https:\/\/www.medicaid.gov\/."},{"key":"2116_CR32","unstructured":"Medicaid. 2026 6\/30\/26]; Available from: https:\/\/www.medicaid.gov\/."},{"issue":"12","key":"2116_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1200\/OP-25-00874","volume":"21","author":"NB Henrikson","year":"2025","unstructured":"Henrikson NB, et al. Financial navigation for people newly diagnosed with cancer: primary outcomes from the cancer financial experience randomized trial. JCO Oncol Pract. 2025;21(12):1817\u201329.","journal-title":"JCO Oncol Pract"},{"key":"2116_CR34","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1016\/j.jbusres.2015.12.002","volume":"69","author":"SM Smith","year":"2016","unstructured":"Smith SM, et al. A multi-group analysis of online survey respondent data quality: comparing a regular USA consumer panel to MTurk samples. J Bus Res. 2016;69:3139\u201348.","journal-title":"J Bus Res"},{"key":"2116_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jbef.2017.12.004","volume":"17","author":"S Palan","year":"2018","unstructured":"Palan S, Schitter C. Prolific.ac\u2014a subject pool for online experiments. J Behav Exp Finance. 2018;17:22\u20137.","journal-title":"J Behav Exp Finance"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-026-02116-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:06:02Z","timestamp":1788465962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-026-02116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":35,"alternative-id":["2116"],"URL":"https:\/\/doi.org\/10.1007\/s11764-026-02116-z","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}